- Bone Metabolism
- Emerging Therapies for Osteoporosis
-
Michael R. McClung
-
Endocrinol Metab. 2015;30(4):429-435. Published online December 31, 2015
-
DOI: https://doi.org/10.3803/EnM.2015.30.4.429
-
-
4,430
View
-
47
Download
-
23
Web of Science
-
21
Crossref
-
Abstract
PDFPubReader
Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage clinical development will be discussed. Abaloparatide (recombinant parathyroid hormone related peptide [PTHrP] analogue) has anabolic activity like teriparatide. Recent data from the phase 3 fracture prevention trial demonstrate that this agent is effective in reducing fracture risk. Inhibiting cathepsin K reduces bone resorption without decreasing the numbers or activity of osteoclasts, thereby preserving or promoting osteoblast function. Progressive increases in bone mineral density (BMD) have been observed over 5 years. Early data suggest that odanacatib effectively reduces fracture risk. Lastly, inhibiting sclerostin with humanized antibodies promotes rapid, substantial but transient increases in bone formation while inhibiting bone resorption. Marked increases in BMD have been observed in phase 2 studies. Fracture prevention studies are underway. The new therapies with novel and unique mechanisms of action may, alone or in combination, provide more effective treatment options for our patients.
-
Citations
Citations to this article as recorded by
- The osteocyte as a signaling cell
Jesus Delgado-Calle, Teresita Bellido Physiological Reviews.2022; 102(1): 379. CrossRef - Combining sclerostin neutralization with tissue engineering: An improved strategy for craniofacial bone repair
Sophie Maillard, Ludovic Sicard, Caroline Andrique, Coralie Torrens, Julie Lesieur, Brigitte Baroukh, Thibaud Coradin, Anne Poliard, Lotfi Slimani, Catherine Chaussain Acta Biomaterialia.2022; 140: 178. CrossRef - Effects of sclerostin antibody on bone healing
Atsushi Mihara, Kiminori Yukata, Toshihiro Seki, Ryuta Iwanaga, Norihiro Nishida, Kenzo Fujii, Yuji Nagao, Takashi Sakai World Journal of Orthopedics.2021; 12(9): 651. CrossRef - Combining Sclerostin Neutralization with Tissue Engineering: An Improved Strategy for Craniofacial Bone Repair
Sophie Maillard, Ludovic Sicard, Caroline Andrique, Coralie Torrens, Julie Lesieur, Brigitte Baroukh, Thibaud Coradin, Anne Poliard, Lotfi Slimani, Catherine Chaussain SSRN Electronic Journal.2021;[Epub] CrossRef - Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures
Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh Endocrinology and Metabolism.2020; 35(1): 55. CrossRef - Clinical Application of Teriparatide in Fracture Prevention
Yuehong Chen, Ronghan Liu, Aubryanna Hettinghouse, Shuya Wang, Gang Liu, Chuan-ju Liu JBJS Reviews.2019; 7(1): e10. CrossRef - The Emerging Role of Osteocytes in Cancer in Bone
Emily G Atkinson, Jesús Delgado‐Calle JBMR Plus.2019;[Epub] CrossRef - Osteoporosis therapies might lead to intervertebral disc degeneration via affecting cartilage endplate
Zhen Sun, Zhuo-Jing Luo Medical Hypotheses.2019; 125: 5. CrossRef - Polymersome nanoparticles for delivery of Wnt-activating small molecules
Edoardo Scarpa, Agnieszka A Janeczek, Alethia Hailes, Maria C de Andrés, Antonio De Grazia, Richard OC Oreffo, Tracey A Newman, Nicholas D Evans Nanomedicine: Nanotechnology, Biology and Medicine.2018; 14(4): 1267. CrossRef - Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects
Jing Wu, Qi Shen, Wei Cui, Yu Zhao, Yue Huai, Yu-chao Zhang, Bei-hua Bao, Chen-xi Liu, Qing Jiang, Jian-xin Li Acta Pharmacologica Sinica.2018; 39(2): 230. CrossRef - Abaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis
Chee Kian Chew, Bart L. Clarke Maturitas.2017; 97: 53. CrossRef - Dried and free flowing granules of Spinacia oleracea accelerate bone regeneration and alleviate postmenopausal osteoporosis
Sulekha Adhikary, Dharmendra Choudhary, Naseer Ahmad, Sudhir Kumar, Kapil Dev, Naresh Mittapelly, Gitu Pandey, Prabhat Ranjan Mishra, Rakesh Maurya, Ritu Trivedi Menopause.2017; 24(6): 686. CrossRef - Romosozumab for the treatment of osteoporosis
Leonardo Bandeira, E. Michael Lewiecki, John P. Bilezikian Expert Opinion on Biological Therapy.2017; 17(2): 255. CrossRef - The quest for new drugs to prevent osteoporosis-related fractures
T. J. de Villiers Climacteric.2017; 20(2): 103. CrossRef - Role and mechanism of action of sclerostin in bone
Jesus Delgado-Calle, Amy Y. Sato, Teresita Bellido Bone.2017; 96: 29. CrossRef - Biochemical Testing Relevant to Bone
Chee Kian Chew, Bart L. Clarke Endocrinology and Metabolism Clinics of North America.2017; 46(3): 649. CrossRef - Re-Invigorating the Osteoporosis Message
Michael R. McClung Endocrine Practice.2016; 22(9): 1130. CrossRef - Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis
Leonardo Bandeira, E. Michael Lewiecki, John P. Bilezikian Expert Opinion on Drug Metabolism & Toxicology.2016; 12(6): 681. CrossRef - Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?
Michael Pazianas, Bo Abrahamsen Annals of the New York Academy of Sciences.2016; 1376(1): 5. CrossRef - Anti-senescence and Anti-inflammatory Effects of the C-terminal Moiety of PTHrP Peptides in OA Osteoblasts
Julia Platas, Maria Isabel Guillén, Francisco Gomar, Miguel Angel Castejón, Pedro Esbrit, Maria José Alcaraz The Journals of Gerontology Series A: Biological Sciences and Medical Sciences.2016; : glw100. CrossRef - Osteocytic signalling pathways as therapeutic targets for bone fragility
Lilian I. Plotkin, Teresita Bellido Nature Reviews Endocrinology.2016; 12(10): 593. CrossRef
|